Differences in Treatment Outcome and Current Cognitive and Behavioral Functioning of Individuals Who Received Ibogaine-Assisted Treatment for a SUD Alan.

Slides:



Advertisements
Similar presentations
What is the evidence for time limiting addiction treatment?
Advertisements

Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Significance of “Unofficial” Ibogaine Treatment Scenes The existence of these scenes indicates demand for alternatives to existing treatment options. Averse.
The Catalyst Group, LLC Adolescent Residential Treatment Initiative I Mua Mau Ohana Project Preliminary Findings Richard Kim, Ph.D. 03/03/2005 Funded by.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence April 2008.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,
® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.
Psychopharmacotherapy in Correctional Institutions Robert P. Schwartz, M.D. Friends Research Institute Supported by NIDA R01 DA (PI: Kinlock)
Nursing Care Makes A Difference The Application of Omaha Documentation System on Clients with Mental Illness.
Using Research/Evaluation Questions to Define Data Collection and Findings: Findings from the FY 2004 KTOS Follow-up Study Robert Walker, Allison Mateyoke-Scrivener,
NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.
® Introduction Back Pain Flare Ups, Physical Function, and Opioid Use Adriana Gonzalez, Darryl White MD, Sandra Burge PhD The University of Texas Health.
C:\laam\lamAPA.ppt 8/04/98 Heroin Addiction Treatment: A Comparison of Methadone and LAAM M. Douglas Anglin, Ph.D. Douglas Longshore, Ph.D. Jeffrey J.
Results of the Vivitrol Pilot in Los Angeles County Presented by: Desiree A. Crevecoeur-MacPhail, Ph.D. Research Psychologist, UCLA ISAP.
Chapter 11 Subset of Overview by Mental Health Disorders GAIN Coordinating Center (11/21/2012). Normal, IL: Chestnut Health Systems. November Available.
Obtaining housing associated with achieving abstinence after detoxification in adults with addiction Tae Woo Park, Christine Maynié-François, Richard Saitz.
Procedural Interventions And Chronic Low Back Pain: Changes Over One Year This sample included 137 patients with complete surveys and chart reviews; 74%
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
Retrospective evaluation of ASAM criteria in adolescents receiving weekly outpatient treatment for co-occurring psychiatric and substance use disorders.
Participants were recruited from 6 drug free, psychosocial treatment (PT) and 5 methadone maintenance (MM) programs (N = 628) participating in a NIDA Clinical.
Patient and Staff Satisfaction in Outpatient Substance Abuse Treatment Programs A. Kulaga 1, B. McClure 1, J. Rotrosen 1, P. Crits-Christoph 2, S. Ring-Kurtz.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter.
Chapter 6 Subset of Overview by Gender GAIN Coordinating Center (11/21/2012). Normal, IL: Chestnut Health Systems. November Available from
Chapter 13 Subset of Overview by Crime and Violence GAIN Coordinating Center (11/21/2012). Normal, IL: Chestnut Health Systems. November Available.
Smoking and Mental Health Problems in Treatment-Seeking University Students Eric Heiligenstein, M.D. University of Wisconsin-Madison Health Services Stevens.
Clinical Trial Finds That While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use Among Those Dependent on Prescription Opioids, 91% Were Not.
Chapter 9 Subset of Overview by Risk of Homelessness GAIN Coordinating Center (11/21/2012). Normal, IL: Chestnut Health Systems. November Available.
Chapter 17 Subset of Overview by Type of Treatment GAIN Coordinating Center (11/21/2012). Normal, IL: Chestnut Health Systems. November Available.
Factors associated with concurrent Heroin use among patients on Methadone maintenance treatment in Vietnam from 2008 to 2013 Hoang Nam Thai MD, MPH – CDC/DGHT.
Efficacy of a “One-Shot” Computerized, Individualized Intervention to Increase Condom Use and Decrease STDs among Clinic Patients with Main Partners Diane.
Substance Abuse James May PH.D. Director SAS Richmond Behavioral Health Authority 2011.
Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.
Trends in Access to Substance Abuse Treatment for Women and Men: Jeanne C. Marsh, PhD, Hee-Choon Shin, PhD, Dingcai Cao, PhD University of Chicago.
The Prescription Opioid & Heroin Crisis: Addiction & Medication Assisted Treatment Andrew Kolodny, M.D. Chief Medical Officer, Phoenix House Foundation.
PRESCRITION DRUG ABUSE and the ELDERLY GREGORY BUNT, M.D. Clinical Assistant Professor of Psychiatry NYU School of Medicine Interim Medical Director Samaritan.
Disability After Traumatic Brain Injury among Hispanic Children
Current Concepts in Pain Management
The Highs and Lows of Relapse and Recovery in Opioid Use Disorder
Daniulaityte, R., Falck, R., & Carlson, R. Introduction
Smartphone-Facilitated N-of-1 Trials for Improving Safety of Analgesic Regimens 1David Odineal, 2Rima Cabrera, 2Maria Marois, 2Sarah Benedetti, 2Peach.
The Diabetic Retinopathy Clinical Research Network
Understanding Drinking among Emerging Adults using the Dualistic Model of Passion: Associations with Alcohol Consumption, Blackouts, and Overdose Alan.
Alcohol, Other Drugs, and Health: Current Evidence
Orion Mowbray, PhD University of Georgia Brian Perron, PhD
L.S. Remy1, G. Woody2, K. Lynch2, K. M. Kampman2
McLean Hospital Division of Alcohol and Drug Abuse
53 Other Primary Diagnosis
Sacred Plants as Medicines for Substance Abuse Rehabilitation
The Myths and Realities of the Opioid Epidemic AMERSA November 3, 2017
6th Annual Residential Substance Abuse Treatment Conference
Department of Health Management and Informatics
ABCs of Behavioral Support
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Bidirectional Association Between Homelessness and Incarceration Among Veterans Participating in HUD-VASH Dennis Culhane, PhD.
Opioids in Butte County
Todd Davis, MD, MMM EVP & CMO, CaroMont Health
Maintenance Treatment
Assessing Opioid Use Disorder, part 1
Receipt of Medication Treatment after Nonfatal Overdose Among Emerging Adults Sarah M. Bagley, MD, MSc Assistant Professor of Medicine and Pediatrics,
treatment service Authors names
Efforts to Reduce Meth Use and Sexual Risk
Rationale –Evidence Base
The Effect of Interaction with Horses
Results: Specific Aim 2 (cont.)
The relationship between incarceration and opioid addiction treatment
Alcohol, Other Drugs, and Health: Current Evidence
Medically assisted treatment
Presentation transcript:

Differences in Treatment Outcome and Current Cognitive and Behavioral Functioning of Individuals Who Received Ibogaine-Assisted Treatment for a SUD Alan K. Davis, Ph.D.1,2, Joseph Barsuglia, Ph.D.2, Martin Polanco, M.D.2 1Bowling Green State University, Bowling Green, OH, 2Crossroads Treatment Center, Rosarito, Mexico Opioid Problem & Current Treatment in the US Pre-Ibogaine Substance Use and Treatment Drug overdose is the leading cause of death in the US and opioid addiction is driving this epidemic American Society of Addiction Medicine, 2016 Opioid replacement (e.g., methadone) is the most popular current treatment for opioid addiction Problems with misuse of ORTs Primary Substance Effectiveness of Ibogaine Treatment Number of days used primary substance Self-reported level of substance use following Ibogaine treatment Duration of craving decrease and mood increase Self-reported effectiveness of Ibogaine treatment Differences in demographics, substance use patterns, and Ibogaine experiences by treatment response group Current Psychological Functioning by Post-Treatment Substance Pattern Treatment Responders: Abstinent or use decreased Treatment Non-responders: Use stayed the same or increased Significantly larger proportion of responders were female (89% vs. 70%) and from a diverse ethnic background (100% vs. 72%) 84% of non-responders returned to consistent use within 6 months 44% of non-responders returned to use within two weeks post-treatment Responders agreed significantly more strongly with the following Ibogaine experience statements: Spiritually meaningful; Personally meaningful; Gained insight into the cause of [his or her] addiction; Experienced unitive oneness; Released feelings of unhealthy shame or guilt. Background: Ibogaine Research Ibogaine, a psychedelic substance, catalyzes an altered state of consciousness reminiscent of dreaming while fully awake so that life experiences, memories, and problems related to past trauma can be confronted and processed. Preliminary evidence suggests this substance acts as an addiction interrupter, reducing or ameliorating withdrawal and craving for opioids and other substances (Alper et al., 1999; Mash, Kovera, & Pablo, 2001; Bastians & Kaplan, 2004; Shenberg et al., 2014). Human studies on the efficacy of this treatment are limited, and outcome studies on the long term benefit and effects of this treatment are even fewer. This retrospective study evaluated the effect of Ibogaine treatment on substance use, craving, mental health, & wellbeing. Subjective Ibogaine Experiences Abstinence Outcomes Proportion abstinent from primary substance for at least 6 months prior to study Proportion abstinent from ALL substances for at least 6 months prior to study Psychospiritual Experiences Visual Experiences Rx Opioid Users Heroin Users Rx Opioid Users Heroin Users Method & Sample Characteristics Summary & Future Directions Using an electronic recruitment & data collection procedure, we collected data from 101 patients with opioid or polysubstance use disorders who had completed Ibogaine treatment at Crossroads Treatment Center between 2011 and 2015. Majority of the sample was male (72%), Caucasian (89%), between 25-54 (82%), and had at least some college (82%). Ibogaine appears to be an effective (initial and long-term abstinence/reduction) addiction interrupter for many people Vast majority view Ibogaine as effective (80%) & better than other treatments (86%) These results highlight the differences in substance use patterns following Ibogaine treatment and the importance of understanding the effects of specific factors related to personal and spiritual experiences during Ibogaine treatment on outcomes. Future research should also evaluate the efficacy of this treatment using a randomized controlled trial design.